Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

The dawn of immunotherapy for breast cancer.

Emens LA.

Clin Adv Hematol Oncol. 2019 Jun;17(6):332-335. No abstract available.

PMID:
31437135
2.

Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.

Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, Oaknin A, Hamilton E, Wang Y, Sarkar I, Molinero L, Fassò M, O'Hear C, Lin YG, Emens LA.

Gynecol Oncol. 2019 Aug;154(2):314-322. doi: 10.1016/j.ygyno.2019.05.021. Epub 2019 Jun 14.

PMID:
31204078
3.

Development of [18F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide.

Lesniak WG, Mease RC, Chatterjee S, Kumar D, Lisok A, Wharram B, Kalagadda VR, Emens LA, Pomper MG, Nimmagadda S.

Mol Imaging. 2019 Jan-Dec;18:1536012119852189. doi: 10.1177/1536012119852189.

4.

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply.

Schmid P, Chui SY, Emens LA.

N Engl J Med. 2019 Mar 7;380(10):987-988. doi: 10.1056/NEJMc1900150. No abstract available.

PMID:
30855757
5.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, de Olza MO, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL.

Clin Cancer Res. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740. Epub 2019 Feb 15.

PMID:
30770348
6.

Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis.

Emens LA, Davis SL, Oliver SCN, Lieu CH, Reddy A, Solomon S, He L, Morley R, Fassò M, Pirzkall A, Patel H, O'Hear C, Ferrara D.

JAMA Ophthalmol. 2019 Jan 1;137(1):96-100. doi: 10.1001/jamaophthalmol.2018.5191.

PMID:
30383154
7.

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators.

N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.

PMID:
30345906
8.

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.

Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fassò M, Molinero L, Schmid P.

JAMA Oncol. 2019 Jan 1;5(1):74-82. doi: 10.1001/jamaoncol.2018.4224.

9.

STING signaling: a key to therapeutic tumor immunity.

Foote JB, Emens LA.

Immunotherapy. 2018 Jul;10(9):729-731. doi: 10.2217/imt-2018-0064. No abstract available.

PMID:
30008260
10.

Targeting adenosine for cancer immunotherapy.

Leone RD, Emens LA.

J Immunother Cancer. 2018 Jun 18;6(1):57. doi: 10.1186/s40425-018-0360-8.

11.

The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.

Arias-Pulido H, Cimino-Mathews A, Chaher N, Qualls C, Joste N, Colpaert C, Marotti JD, Foisey M, Prossnitz ER, Emens LA, Fiering S.

Breast Cancer Res Treat. 2018 Sep;171(2):273-282. doi: 10.1007/s10549-018-4834-7. Epub 2018 Jun 1.

12.

Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.

Litvak A, Batukbhai B, Russell SD, Tsai HL, Rosner GL, Jeter SC, Armstrong D, Emens LA, Fetting J, Wolff AC, Silhy R, Stearns V, Connolly RM.

Cancer. 2018 May 1;124(9):1904-1911. doi: 10.1002/cncr.31260. Epub 2018 Jan 30.

13.

Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.

Hung CF, Xu X, Li L, Ma Y, Jin Q, Viley A, Allen C, Natarajan P, Shivakumar R, Peshwa MV, Emens LA.

Hum Gene Ther. 2018 May;29(5):614-625. doi: 10.1089/hum.2017.080. Epub 2018 Apr 2.

14.

Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.

Ojalvo LS, Thompson ED, Wang TL, Meeker AK, Shih IM, Fader AN, Cimino-Mathews A, Emens LA.

Hum Pathol. 2018 Apr;74:135-147. doi: 10.1016/j.humpath.2017.12.010. Epub 2017 Dec 27.

PMID:
29288043
15.

Report on the Third FDA-AACR Oncology Dose-Finding Workshop.

Emens LA, Bruno R, Rubin EH, Jaffee EM, McKee AE.

Cancer Immunol Res. 2017 Dec;5(12):1058-1061. doi: 10.1158/2326-6066.CIR-17-0590.

16.

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.

Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, Lippman ME, Somer R, Smakal M, Emens LA, Hrinczenko B, Edenfield W, Gurtler J, von Heydebreck A, Grote HJ, Chin K, Hamilton EP.

Breast Cancer Res Treat. 2018 Feb;167(3):671-686. doi: 10.1007/s10549-017-4537-5. Epub 2017 Oct 23.

17.

Breast Cancer Immunotherapy: Facts and Hopes.

Emens LA.

Clin Cancer Res. 2018 Feb 1;24(3):511-520. doi: 10.1158/1078-0432.CCR-16-3001. Epub 2017 Aug 11. Review.

18.

PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast.

Thompson ED, Taube JM, Asch-Kendrick RJ, Ogurtsova A, Xu H, Sharma R, Meeker A, Argani P, Emens LA, Cimino-Mathews A.

Mod Pathol. 2017 Nov;30(11):1551-1560. doi: 10.1038/modpathol.2017.79. Epub 2017 Jul 21.

19.

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B, Marincola FM.

Eur J Cancer. 2017 Aug;81:116-129. doi: 10.1016/j.ejca.2017.01.035. Epub 2017 Jun 15. Review.

PMID:
28623775
20.

A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.

Foote JB, Kok M, Leatherman JM, Armstrong TD, Marcinkowski BC, Ojalvo LS, Kanne DB, Jaffee EM, Dubensky TW Jr, Emens LA.

Cancer Immunol Res. 2017 Jun;5(6):468-479. doi: 10.1158/2326-6066.CIR-16-0284. Epub 2017 May 8.

21.

Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo.

Sunay MM, Foote JB, Leatherman JM, Edwards JP, Armstrong TD, Nirschl CJ, Hicks J, Emens LA.

Int Immunopharmacol. 2017 May;46:112-123. doi: 10.1016/j.intimp.2017.02.028. Epub 2017 Mar 7.

22.

Specific immunotherapy in ovarian cancer: a systematic review.

Alipour S, Zoghi S, Khalili N, Hirbod-Mobarakeh A, Emens LA, Rezaei N.

Immunotherapy. 2016 Oct;8(10):1193-204. doi: 10.2217/imt-2016-0034. Review.

PMID:
27605068
23.

It's TIME for a biomarker-driven approach to cancer immunotherapy.

Emens LA.

J Immunother Cancer. 2016 Aug 16;4:43. doi: 10.1186/s40425-016-0147-8. eCollection 2016. No abstract available.

24.

Cancer immunotherapy trials: leading a paradigm shift in drug development.

Emens LA, Butterfield LH, Hodi FS Jr, Marincola FM, Kaufman HL.

J Immunother Cancer. 2016 Jul 19;4:42. doi: 10.1186/s40425-016-0146-9. eCollection 2016. No abstract available.

25.

Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y.

VandenBussche CJ, Cimino-Mathews A, Park BH, Emens LA, Tsangaris TN, Argani P.

Am J Surg Pathol. 2016 Aug;40(8):1090-9. doi: 10.1097/PAS.0000000000000674.

PMID:
27299796
26.

Targeting the programmed cell death-1 pathway in breast and ovarian cancer.

Emens LA, Kok M, Ojalvo LS.

Curr Opin Obstet Gynecol. 2016 Apr;28(2):142-7. doi: 10.1097/GCO.0000000000000257.

PMID:
26881392
27.

The immune microenvironment of breast ductal carcinoma in situ.

Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN, Argani P, Cimino-Mathews A, Emens LA.

Mod Pathol. 2016 Mar;29(3):249-58. doi: 10.1038/modpathol.2015.158. Epub 2016 Jan 15.

28.

PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.

Cimino-Mathews A, Thompson E, Taube JM, Ye X, Lu Y, Meeker A, Xu H, Sharma R, Lecksell K, Cornish TC, Cuka N, Argani P, Emens LA.

Hum Pathol. 2016 Jan;47(1):52-63. doi: 10.1016/j.humpath.2015.09.003. Epub 2015 Sep 21.

29.

Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer.

Emens LA, Romero P.

J Immunother Cancer. 2015 Oct 20;3:49. doi: 10.1186/s40425-015-0092-y. eCollection 2015. No abstract available.

30.

Emerging immunotherapies in ovarian cancer.

Ojalvo LS, Nichols PE, Jelovac D, Emens LA.

Discov Med. 2015 Sep;20(109):97-109. Review.

31.

Antagonists of PD-1 and PD-L1 in Cancer Treatment.

Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL.

Semin Oncol. 2015 Aug;42(4):587-600. doi: 10.1053/j.seminoncol.2015.05.013. Epub 2015 Jun 10. Review.

32.

Chemotherapy--A Viable Partner for Cancer Immunotherapy?

Emens LA.

JAMA Oncol. 2015 Nov;1(8):1095-7. doi: 10.1001/jamaoncol.2015.2733. No abstract available.

PMID:
26291503
33.

Immune targeting in breast cancer.

Cimino-Mathews A, Foote JB, Emens LA.

Oncology (Williston Park). 2015 May;29(5):375-85. Review.

34.

The interplay of immunotherapy and chemotherapy: harnessing potential synergies.

Emens LA, Middleton G.

Cancer Immunol Res. 2015 May;3(5):436-43. doi: 10.1158/2326-6066.CIR-15-0064. Review.

35.

Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramatically increases health care costs.

VandenBussche CJ, Cimino-Mathews A, Park BH, Emens LA, Tsangaris TN, Argani P.

Am J Surg Pathol. 2015 Jul;39(7):939-47. doi: 10.1097/PAS.0000000000000424.

PMID:
25871620
36.

A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.

Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dauses T, Fetting J, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V, Jaffee EM, Emens LA.

Cancer Immunol Res. 2014 Oct;2(10):949-61. doi: 10.1158/2326-6066.CIR-14-0058. Epub 2014 Aug 12.

37.

A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway.

Cimino-Mathews A, Hicks JL, Sharma R, Vang R, Illei PB, De Marzo A, Emens LA, Argani P.

Hum Pathol. 2013 Nov;44(11):2494-500. doi: 10.1016/j.humpath.2013.06.009. Epub 2013 Jul 31.

38.

Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.

Cimino-Mathews A, Ye X, Meeker A, Argani P, Emens LA.

Hum Pathol. 2013 Oct;44(10):2055-63. doi: 10.1016/j.humpath.2013.03.010. Epub 2013 May 21.

39.

HER2-directed therapy for metastatic breast cancer.

Jelovac D, Emens LA.

Oncology (Williston Park). 2013 Mar;27(3):166-75. Review.

40.

Chemoimmunotherapy: reengineering tumor immunity.

Chen G, Emens LA.

Cancer Immunol Immunother. 2013 Feb;62(2):203-16. doi: 10.1007/s00262-012-1388-0. Epub 2013 Feb 7. Review.

41.

Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.

Emens LA.

Expert Rev Anticancer Ther. 2012 Dec;12(12):1597-611. doi: 10.1586/era.12.147. Review.

42.

Toward integrative cancer immunotherapy: targeting the tumor microenvironment.

Emens LA, Silverstein SC, Khleif S, Marincola FM, Galon J.

J Transl Med. 2012 Apr 10;10:70. doi: 10.1186/1479-5876-10-70.

43.

Re-purposing cancer therapeutics for breast cancer immunotherapy.

Emens LA.

Cancer Immunol Immunother. 2012 Aug;61(8):1299-305. doi: 10.1007/s00262-012-1247-z. Epub 2012 Mar 28. Review.

44.

A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer.

Higgins MJ, Prowell TM, Blackford AL, Byrne C, Khouri NF, Slater SA, Jeter SC, Armstrong DK, Davidson NE, Emens LA, Fetting JH, Powers PP, Wolff AC, Green H, Thibert JN, Rae JM, Folkerd E, Dowsett M, Blumenthal RS, Garber JE, Stearns V.

Breast Cancer Res Treat. 2012 Feb;131(3):915-24. doi: 10.1007/s10549-011-1858-7. Epub 2011 Nov 11.

45.

Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.

Prowell TM, Blackford AL, Byrne C, Khouri NF, Dowsett M, Folkerd E, Tarpinian KS, Powers PP, Wright LA, Donehower MG, Jeter SC, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Garrett-Mayer E, Skaar TC, Davidson NE, Stearns V.

Cancer Prev Res (Phila). 2011 Dec;4(12):1993-2001. doi: 10.1158/1940-6207.CAPR-11-0154. Epub 2011 Sep 1.

46.

Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.

Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, Zhao M, Fetting JH, Emens LA, Stearns V, Davidson NE, Baker SD, Wolff AC.

Breast Cancer Res Treat. 2011 May;127(1):153-62. doi: 10.1007/s10549-011-1413-6. Epub 2011 Feb 25.

47.

Chemoimmunotherapy.

Emens LA.

Cancer J. 2010 Jul-Aug;16(4):295-303. doi: 10.1097/PPO.0b013e3181eb5066. Review.

48.

GM-CSF-secreting vaccines for solid tumors: moving forward.

Gupta R, Emens LA.

Discov Med. 2010 Jul;10(50):52-60. Review.

49.

The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE₂ in murine macrophages.

Edwards JP, Emens LA.

Int Immunopharmacol. 2010 Oct;10(10):1220-8. doi: 10.1016/j.intimp.2010.07.002. Epub 2010 Jul 15.

50.

Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice.

Pfannenstiel LW, Lam SS, Emens LA, Jaffee EM, Armstrong TD.

Cell Immunol. 2010;263(1):79-87. doi: 10.1016/j.cellimm.2010.03.001. Epub 2010 Mar 6.

Supplemental Content

Loading ...
Support Center